White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration

详细信息    查看全文

• 作者：Benjamin M. Kandel^a ; ^{bkandel@seas.upenn.edu" class="auth_mail" title="E-mail the corresponding author} ; Brian B. Avants^b ; James C. Gee^b ; Corey T. McMillan^c ; Guray Erus^d ; Jimit Doshi^d ; Christos Davatzikos^d ; David A. Wolk^c ; for the Alzheimer's Disease Neuroimaging Initiative
• 关键词：Alzheimer's disease ; Aging ; MRI ; PET ; White matter ; Leukoaraiosis ; Preclinical Alzheimer's disease ; Amyloid
• 刊名：Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
• 出版年：2016
• 出版时间：2016
• 年：2016
• 卷：4
• 期：Complete
• 页码：18-27
• 全文大小：422 K

文摘

Cognitive tests and nonamyloid imaging biomarkers do not consistently identify preclinical AD. The objective of this study was to evaluate whether white matter hyperintensity (WMH) volume, a cerebrovascular disease marker, is more associated with preclinical AD than conventional AD biomarkers and cognitive tests.

Methods

Elderly controls enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI, n = 158) underwent florbetapir-PET scans, psychometric testing, neuroimaging with MRI and PET, and APOE genetic testing. Elderly controls the Parkinson's progression markers initiative (PPMI, n = 58) had WMH volume, cerebrospinal fluid (CSF) Aβ_1–42, and APOE status measured.

Results

In the ADNI cohort, only WMH volume and APOE ε4 status were associated with cerebral Aβ (standardized β = 0.44 and 1.25, P = .03 and .002). The association between WMH volume and APOE ε4 status with cerebral Aβ (standardized β = 1.12 and 0.26, P = .048 and .045) was confirmed in the PPMI cohort.

Discussion

WMH volume is more highly associated with preclinical AD than other AD biomarkers.